Hibor (bemiparin) / ROVI Pharmaceuticals Laboratories, Elder Pharma - LARVOL DELTA

Severe Peripartum Cardiomyopathy With Complete Functional Recovery: The Role of Multimodality Imaging and Optimized Medical Therapy. (PubMed, Cureus) - "Comprehensive management included therapeutic anticoagulation (initially with bemiparin), early guideline-directed medical therapy, and a prolonged 12-week course of bromocriptine. This case illustrates that clinical and conventional echocardiographic recovery in PPCM may mask persistent subclinical myocardial dysfunction. It emphasizes the necessity of multimodality imaging, specifically speckle-tracking strain analysis and tissue characterization, to accurately define the true spectrum of myocardial recovery and guide long-term risk stratification."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Gynecology • Heart Failure • Hematological Disorders • Immunology • Thrombosis

Markers in umbilical cord blood in early-onset fetal growth restricted fetuses. (PubMed, Placenta) - "Early-onset FGR is associated with a distinct fetal profile characterized by endothelial activation and angiogenic imbalance, independent of prematurity. Prophylactic LMWH initiated at diagnosis did not modify these pathways, suggesting that fetal alterations are already established and not responsive to treatment at this stage. These findings support the need for earlier or alternative therapeutic strategies targeting placental dysfunction."

Journal • Inflammation • ENG • IL6 • LEP • LEPR

Thromboinflammatory and Pharmacological Effects of Low-Molecular-Weight Heparins in Acute Venous Thromboembolism: An Integrated Clinical and In Silico Analysis. (PubMed, Med Sci (Basel)) - "This study compared enoxaparin, bemiparin, and tinzaparin and explored potential multi-target mechanisms using molecular docking, network pharmacology, and enrichment analyses. LMWH therapy was associated with improved thromboinflammatory markers and clinical recovery, with tinzaparin showing comparatively more favorable thromboinflammatory biomarker trajectories and recovery dynamics within the limitations of this observational analysis. Integrated clinical and in silico findings provide hypothesis-generating insights into potential multi-target pharmacological effects beyond anticoagulation; however, these observations should be interpreted cautiously and require experimental validation."

Biomarker • Journal • Retrospective data • Cardiovascular • Inflammation • Pain • Venous Thromboembolism • IL6

LIVER SAFETY COMPARISON OF BEMIPARIN AND ENOXAPARIN IN PREGNANCY: INSIGHTS FROM A REAL-WORLD STUDY (ISPOR 2026) - "This study suggested that enoxaparin was associated with a significantly higher incidence of liver injury events compared to bemiparin. Therefore, continuous monitoring of liver function is warranted when pregnant patients are treated especially with enoxaparin, and educating patients about the signs of liver injury such as abdominal pain or nausea is also crucial."

Clinical • Real-world • Real-world evidence • Cardiovascular • Hepatology • Immunology • Liver Failure • Renal Disease • Venous Thromboembolism

Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients (clinicaltrials.gov) - P=N/A | N=2400 | Recruiting | Sponsor: Hawler Medical University | Trial completion date: Apr 2026 ➔ Oct 2026 | Trial primary completion date: Feb 2026 ➔ Sep 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Lung Cancer Receiving Chemotherapy (ASH 2023) - "The prophylactic doses of bemiparin, certoparin, dalteparin, nadroparin, semuloparin and tinzaparin, intermediate dose of enoxaparin and prophylactic dose of rivaroxaban and apixaban were used in the studies. In our subgroup meta-analysis of POTP with DOACs, there was no statistically significant difference in reduction of VTE in LC patients with Khorana Score ≥2. Hence, the selection of appropriate patients who are high risk for VTE is crucial and further studies are required to define high risk subsets of LC patients receiving chemotherapy who may benefit from POTP."

Retrospective data • Cardiovascular • Lung Cancer • Oncology • Solid Tumor • Venous Thromboembolism

Liver Safety Comparison of Bemiparin and Enoxaparin in Pregnancy: Insights From a Real-World Study (ISPOR-EU 2025) - "This study suggested that enoxaparin was associated with a significantly higher incidence of liver injury events compared to bemiparin. Therefore, continuous monitoring of liver function is warranted when pregnant patients are treated especially with enoxaparin, and educating patients about the signs of liver injury such as abdominal pain or nausea is also crucial."

Clinical • Real-world • Real-world evidence • Cardiovascular • Hepatology • Immunology • Liver Failure • Renal Disease • Venous Thromboembolism

Effect of Intra-arterial Bemiparin Sodium on Intestinal Ischemia-Reperfusion Injury: Animal Model. (PubMed, J Surg Res) - "Based on our findings in this rat model, intra-arterial bemiparin sodium may exert a protective effect against ischemia-reperfusion injury. Further studies are required to confirm its translational potential."

Journal • Preclinical • Cardiovascular • Gastrointestinal Disorder • Inflammation • Reperfusion Injury • CRP

Neonatal morbidity in early-onset fetal growth restriction with and without anticoagulant therapy. (PubMed, Pediatr Res) - "Prophylactic LMWH started at the diagnosis of early-onset FGR does not decrease neonatal morbidity or NICU stay duration. Its design is a randomized, triple-blind clinical trial, which provides high-quality evidence. LMWH is often prescribed during pregnancy for various indications, and in the absence of effective alternatives, it is increasingly used empirically in such cases. Our findings do not support its use for reducing perinatal morbidity or NICU admission duration."

Clinical • Journal

Whether an optimal strategy exists for VTE prevention in critically ill patients: Insights from guidelines and randomized controlled trials. (PubMed, Eur J Intern Med) - "Although the 17 CPGs propose various strategies for VTE prevention, substantial differences exist in their quality and clinical applicability. Existing clinical evidence fails to demonstrate superior prophylactic efficacy among VTE prevention strategies in critically ill patients."

Journal • Cardiovascular • Hematological Disorders • Respiratory Diseases • Venous Thromboembolism

Anti-PF4/ Heparin Antibodies Early Seroconversion in Hip Fracture Patients Receiving Low Molecular Weight Heparin Prophylaxis: a Pilot Study of 100 Consecutive Patients. (PubMed, Arch Bone Jt Surg) - "Twenty-seven patients received bemiparin, 42 enoxaparin and 25 tinzaparin. These findings highlight the overall safety of LMWHs in elderly hip fracture patients. Moreover, the presence of anti-PF4/H appears unrelated to PLT fluctuations, subsequent VTE events and early postoperative mortality."

Journal • Hematological Disorders • Musculoskeletal Diseases • Orthopedics • Thrombocytopenia

Thromboprophylaxis in oncology patients with active cancer: results from GMaT and ACT4CAT clinical studies (MASCC-ISOO 2025) - "Anticoagulation agents were (%): 91.2 tinzaparin, 4.6 fondaparinux, 2.3 bemiparin, 1.2 enoxaparin, 0.8 rivaroxaban or apixaban, for 5.1±3.3 months duration. Selection of anticoagulation dose was based on demographics, cancer characteristics, treatment type and patient medical history. InterD was found to be more efficacious and without safety concerns."

Clinical • Metabolic Disorders • Oncology • Thrombosis

Influence of anticoagulant concomitant medication on wound healing: Analysis of a multicentre cohort of 212 patients with a uniform wound model. (PubMed, Br J Clin Pharmacol) - "Enoxaparin and nadroparin may enhance wound healing, whereas phenprocoumon, acetylsalicylic acid, and certain low-molecular-weight heparins (certoparin, tinzaparin, dalteparin, bemiparin) appear to delay wound healing. Anticoagulant monotherapy with enoxaparin or nadroparin should be considered postoperatively when feasible."

Journal

Bemiparin in neonatal thrombosis: therapeutic dosing and safety. (PubMed, J Perinatol) - "Bemiparin appears to be a potential therapeutic option for anticoagulation in neonates; however, targeted anti-Xa levels were rarely achieved with the initial dose and most patients required uptitration."

Journal • Cardiovascular • Hematological Disorders • Thrombosis

Factor Xa Inhibitors and Low Molecular Weight Heparins in Perioperative Surgical Thromboprophylaxis: A Network Meta-Analysis. (PubMed, Cardiovasc Hematol Agents Med Chem) - "Rivaroxaban, fondaparinux, edoxaban, and bemiparin are superior perioperative thromboprophylaxis agents than enoxaparin in major surgeries. Fondaparinux and bemiparin have shown the highest risk of major bleeding compared to other factor Xa inhibitors and LMWHs."

Clinical • Journal • Retrospective data • Cardiovascular • Hematological Disorders • Respiratory Diseases • Thrombosis • Venous Thromboembolism

Exploring the use of electroconvulsive therapy in the anticoagulated population: A systematic review. (PubMed, Aust N Z J Psychiatry) - "64.81% patients were on warfarin, 22.22% on a direct-acting oral anticoagulant, 5.55% on heparin and the rest on enoxaparin, dalteparin, acenocoumarol or bemiparin. This review showed tolerability of anticoagulants continued throughout electroconvulsive therapy, with most patients reporting no adverse effects. Given limitations including few studies and medical comorbidities influencing patient risk profile, further studies are required to guide practice recommendations and review long-term outcomes."

Journal • Review • Cardiovascular • Cerebral Hemorrhage • Psychiatry • Pulmonary Embolism • Respiratory Diseases

Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study) (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: AHEPA University Hospital | N=240 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Atrial Fibrillation • Cardiovascular • Oncology

PRIMARY AMBULATORY THROMBOPROPHYLAXIS (PATP) IN PATIENTS WITH LUNG CANCER UNDERGOING SYSTEMIC THERAPY: UPDATED ANALYSIS OF RANDOMIZED STUDIES (EHA 2024) - "5,526 patients with LC from five RCTs and subgroups of another six RCTs were eligible. Bemiparin, certoparin,dalteparin, nadroparin, semuloparin, tinzaparin, enoxaparin, rivaroxaban and apixaban were used. The durationof the anticoagulation ranged from 3 to 6 months."

Clinical • Cardiovascular • Hematological Disorders • Lung Cancer • Oncology • Solid Tumor • Venous Thromboembolism

BEMIPARIN IN ONCOLOGICAL PATIENTS. A SYSTEMATIC REVIEW AND META-ANALYSIS (EHA 2024) - "Our findings indicate that thromboprophylaxis with bemiparin had no statistically significant impact onlowering the risk of VTE in oncological patients. In addition, the results demonstrated no increased risk ofbleeding among these patients. Further RCTs are needed to assess more conclusively the extent of theseresults."

Retrospective data • Review • Cardiovascular • Oncology • Venous Thromboembolism

Anti-Xa level monitoring of low-molecular-weight heparin in patients with thrombosis and cancer (ISTH 2024) - "No statistically significant differences were observed between bemiparin and enoxaparin and tinzaparin for thrombosis and bleeding events. 447 results of anti-Xa activity from 50 patients were analyzed. 108 anti-Xa activity results (24.1%) were in the supratherapeutic range and 34 (7.6%) were infratherapeutic. A result out the therapeutic range in 21 anti-Xa determinations (34.2%) led to modification of the LMWH regimen."

Clinical • Cardiovascular • Hematological Disorders • Oncology • Pulmonary Embolism • Thrombosis • Venous Thromboembolism

Anticoagulants In The Treatment of Primary Antiphospholipid Syndrome In Pregnant Women: A Systematic Review (ISTH 2024) - "Through the inclusion criteria, 3 journals were obtained according to the Randomized Control Trial (RCT), Cohort, and Clinical Trial research description. Based on the Newcastle Ottawa Scale (NOS) and the Jadad Scale, 2 studies were rated good and 1 studies were fair. Based on this research, it was found that in patients with primary antiphospholipid syndrome, the use of anticoagulants with and without low dose aspirin (LDA) resulted in a high live birth rate ranging from 82-86.25%."

Clinical • Review • Cardiovascular • Genetic Disorders • Hematological Disorders • Immunology • Thrombosis

Efficacy and safety of bemiparin as treatment of venous thromboembolic disease in the elderly. (PubMed, J Eval Clin Pract) - "Bemiparin showed a similar efficacy and safety profile in the treatment of venous thromboembolic disease in elderly and adult patients."

Journal • Cardiovascular • Geriatric Disorders • Venous Thromboembolism

ACT for patients with active cancer and high thromboembolic risk: results from the ACT4CAT study (MASCC-AFSOS-ISOO 2024) - "Anticoagulants were: tinzaparin 88.5%, fondaparinux 6.1%, bemiparin 2.5%, enoxaparin 1.7%, apixaban 0.6% and rivaroxaban 0.7%. Conclusions Thromboprophylaxis in patients with active ca is safe & effective. Metastasis, HRTCAs & drug-drug interactions seem that influence a decision for thromboprophylaxis in favor of LMWHs, often on intermediate dose."

Clinical • Cardiovascular • CNS Disorders • Hematological Disorders • Oncology

TRACIP: Treatment of Intrauterine Growth Restriction With Low Molecular Heparin. (clinicaltrials.gov) - P3 | N=48 | Completed | Sponsor: Fundació Sant Joan de Déu | Unknown status ➔ Completed

Trial completion

Treatment with reversible coagulation inhibitors does not provides full coagulation inhibition. (GTH 2024) - "Testing oral anticoagulation with vitamin K antagonists (Warfarin) or with heparinoids (unfractionated heparin, LMW heparin such as Fragmin, Enoxaparin, Bemiparin, and Fondaparinux) showed for heparinoids a similar delay and stop of growth, but surprisingly for vitamin K antagonists a reduced but not a stop of growth...Testing reversible inhibitors of factor Xa (Rivaroxaban, Apixaban, Edoxaban) and of factor IIa (Dabigatran, Argatroban) showed a maximal reduction of about 50% in growth for quite a prolonged time (> 1 hr), but no stop...The profile of the inhibitors may be used to match the clinical need and the pathological process. The suggestion can be made that new Xa-DOACs may be selected to be more potent, tight inhibitors of the factor Xa formed by the intrinsic tenase (factor IX, factor VIII) which is involved in clot growth."